CRISPR Market

The CRISPR market is projected to reach USD 6.12 billion by 2031 from USD 3.48 billion in 2026, at a CAGR of 12.0% during the forecast period.

Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), and Merck KGaA (Germany) are the key players in this market.

To know about the assumptions considered for the study download the pdf brochure

These market players have adopted various strategies, including portfolio expansion, collaborations, investments, advanced genome-editing technologies, and product and service development, to strengthen their market positions. In September 2025, Revvity and Profluent entered into a strategic collaboration combining Revvity's Pin-point base editing platform with Profluent's AI-engineered proteins to create AI-enhanced adenine deaminase base-editing systems. The collaboration also builds on integrating Profluent's OpenCRISPR nuclease with the Pin-point platform, expanding access to customizable next-generation gene-editing systems.

In July 2025, Merck KGaA launched PURedit Cas9 Cytosine Base Editors, a CRISPR-Cas9 RNP-based editing solution designed to enable precise C-to-T substitutions without inducing double-stranded DNA breaks.

Thermo Fisher Scientific Inc. (US): Thermo Fisher supports CRISPR workflows through an integrated portfolio covering gRNA design and synthesis, Cas9 proteins, CRISPR libraries, transfection, cell engineering, genome-editing validation, and genetic analysis. Its TrueDesign Genome Editor supports gRNA design, while TrueGuide synthetic gRNAs and TrueCut Cas9 proteins support genome-editing experiments. The company also provides CRISPR libraries for high-throughput screening and analytical tools for edit confirmation and characterization, enabling integration of CRISPR products and services across research workflows.

Agilent Technologies, Inc. (US): Agilent provides CRISPR capabilities centered on guide RNA design, synthesis, quality control, and scalable manufacturing. Its SureGuide portfolio includes chemically synthesized sgRNAs with customizable modifications and quality-control capabilities, while its ClinGuide CRISPR sgRNA offering supports cGMP manufacturing for clinical and commercial genome-editing programs. Agilent has also expanded manufacturing capacity for CRISPR guide RNAs and supports CRISPR-based cell engineering and immunotherapy workflows, strengthening its position across research and translational applications.

Merck KGaA (Germany): Merck supports the CRISPR market through its Life Science business, offering CRISPR reagents, genome-editing products, CRISPR libraries, screening solutions, and analytical capabilities. The company has a long-standing presence in genome editing and has developed CRISPR technologies and intellectual property while supporting research applications through its gene-editing portfolio. Merck also provides technologies and process support to emerging biotechnology companies developing gene-editing platforms, extending its CRISPR capabilities from research tools toward translational and therapeutic development.

Market Ranking

The CRISPR market is competitive, with established life science companies strengthening their market positions through portfolio expansion, strategic collaborations, advanced genome-editing technologies, and integrated product and service offerings. Key players include Thermo Fisher Scientific Inc. (US), Agilent Technologies, Inc. (US), and Merck KGaA (Germany). Thermo Fisher Scientific supports CRISPR workflows through genome-editing reagents, guide RNA solutions, CRISPR libraries, and related research services. Agilent Technologies focuses on CRISPR guide RNA design, synthesis, quality control, and manufacturing capabilities. Merck KGaA offers CRISPR reagents, genome-editing technologies, libraries, and screening solutions through its Life Science business. Collectively, these companies support the CRISPR market through genome-editing products, guide RNA design and synthesis, screening, validation, and integrated research and translational workflows.

Related Reports:

CRISPR Market by Offering (Products [Kits, Enzymes, Libraries], Services [gRNA Synthesis, Cell Line Development, Screening, Validation]), Application (Drug Discovery, Development, Agriculture), End User, Competition, Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]